SNOA
Sonoma Pharmaceuticals, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Sonoma Pharmaceuticals, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
No thesis.
No other changes.
No other changes.
Largest filed tie
0
filed ties
—
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; Lasercyn gel intended for the management of minor skin irritations; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Gramaderm for the treatment of topical mild to moderate acne; Microsafe, a surface disinfectant; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; Lasercyn gel intended for the management of minor skin irritations; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Gramaderm for the treatment of topical mild to moderate acne; Microsafe, a surface disinfectant; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
Annual filing, covered
10-K parsed · Jun 16 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Jun 16 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Sonoma Pharmaceuticals, Inc.
1.10
pre 1.14 +3.64%
—
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; no measured co-movers for Sonoma Pharmaceuticals, Inc..
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; no measured co-movers for Sonoma Pharmaceuticals, Inc..
Tall tick = annual report · Source: EDGAR
+30.74%
shares held · 10 largest managers
| Manager | Value | % base | |
|---|---|---|---|
| Renaissance Technologies | $49,776 | 36.53% | new |
| Geodeindex-like | $32,947 | 24.18% | +34.33% |
| Vanguardindex-like | $23,108 | 16.96% | 0.00% |
| McKinley Carter Wealth Services | $13,768 | 10.10% | 0.00% |
| UBS | $9,604 | 7.05% | +130033.33% |
| Manager | Value | % base | |
|---|---|---|---|
| Renaissance Technologies | $49,776 | 36.53% | new |
| Geodeindex-like | $32,947 | 24.18% | +34.33% |
| Vanguardindex-like | $23,108 | 16.96% | 0.00% |
| McKinley Carter Wealth Services | $13,768 | 10.10% | 0.00% |
| UBS | $9,604 | 7.05% | +130033.33% |
Bull2
Bear1
Expected move
No implied move.